Abstract:Antiphospholipid syndrome (APS) is associated with a risk of obstetrical complications, affecting both the mother and the fetus. Obstetrical APS is defined by a history of three consecutive spontaneous miscarriages before 10 weeks of gestation (WG), an intra-uterine fetal death after 10 WG, or a premature birth before 34 WG because of severe pre-eclampsia, eclampsia or placental adverse outcomes (intrauterine growth retardation, oligohydramnios). Pregnancy in women with a diagnosis of obstetric APS is at increased risk for placental abruption, HELLP (Hemolysis, Elevated Liver enzymes, Low Platelet count) syndrome and thrombosis that may be part of a catastrophic antiphospholipid syndrome (CAPS). A previous thrombosis and the presence of a lupus anticoagulant are risk factors for pregnancy failure. A multidisciplinary approach, associating the internist, the anesthesiologist and the obstetrician, is recommended for these high-risk pregnancies. Preconception counseling is proposed to identify pregnancy contraindications, and to define and adapt the treatment prior and during the upcoming pregnancy. Heparin and low-dose aspirin are the main treatments. The choice between therapeutic or prophylactic doses of heparin will depend on the patient's medical history. The anticoagulant therapeutic window for delivery should be as narrow as possible and adapted to maternal thrombotic risk. There is a persistent maternal risk in the postpartum period (thrombosis, HELLP syndrome, CAPS) justifying an antithrombotic coverage during this period. We suggest a monthly clinical and biological monitoring which can be more frequent towards the end of pregnancy. The persistence of notches at the Doppler-ultrasound evaluation seems to be the best predictor for a higher risk of placental vascular complications. Treatment optimization and multidisciplinary antenatal care improve the prognosis of pregnancies in women with obstetric APS, leading to a favorable outcome most of the time.

Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome

Treatment of Pregnancy Complications

Obstetric antiphospholipid syndrome: A recent classification for an old defined disorder

Pregnancy in antiphospholipid syndrome: what should a rheumatologist know?

Obstetric Anti-phospholipid Syndrome: State of the Art

Obstetric Antiphospholipid Syndrome From the Perspective of a Rheumatologist

Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review

Obstetric Management of Antiphospholipid Syndrome

Management of Women with Antiphospholipid Antibodies or Antiphospholipid Syndrome during Pregnancy

Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update

Obstetric Antiphospholipid Syndrome: An Update on Pathophysiology and Management

"APS pregnancy - The offspring"

Antiphospholipid Antibodies in Pregnancy: Maternal and Neonatal Implications

Antiphospholipid Syndrome in Pregnancy: New and Old Pathogenetic Mechanisms

[Pregnancy and antiphospholipid syndrome]

Impact of Antiphospholipid Syndrome on Reproductive Outcomes: Current Insights and Management Approaches

Obstetric antiphospholipid syndrome

The impact of various entities of antiphospholipid antibodies positivity on adverse pregnancy outcome. An epidemiological perspective

EULAR recommendations for the management of antiphospholipid syndrome in adults

Obstetric anti-phospholipid syndrome: from pathogenesis to treatment

Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?